Evans syndrome overview: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:


==Historical Perspective==
==Historical Perspective==
Evans syndrome was first described by Dr. Robert S. Evans, an American physician, in 1951.
Evans syndrome was first described by Dr. Robert S. Evans, an American physician, in 1951.Evans suggested that thrombocytopenia was likely due to an autoantibody directed against the platelets.


==Pathophysiology==
==Pathophysiology==

Revision as of 00:18, 28 May 2021

Evans syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Evans syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Evans syndrome overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Evans syndrome overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Evans syndrome overview

CDC on Evans syndrome overview

Evans syndrome overview in the news

Blogs on Evans syndrome overview

Directions to Hospitals Treating Evans syndrome

Risk calculators and risk factors for Evans syndrome overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Evans' Syndrome is an autoimmune disease in which an individual's antibodies attack their own RBCs as well as their platelets. Its overall pathology is therefore effectively a combination of the two autoimmune induced conditions: autoimmune hemolytic anemia and immune thrombocytopenic purpura. Autoimmune hemolytic anemia is a condition in which the red blood cells that normally carry oxygen and carbon dioxide are destroyed by an autoimmune process. Immune thrombocytopenic purpura is a condition in which the platelets in the blood are destroyed by an autoimmune process. Platelets are a component of blood that contribute to the formation of blood clots in the body to prevent bleeding. Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy. Laboratory findings consistent with the diagnosis of Evans syndrome include anemia, direct coombs test positive, and antineutrophil antibody positive. Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab. Surgery is not the first­line treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment.

Historical Perspective

Evans syndrome was first described by Dr. Robert S. Evans, an American physician, in 1951.Evans suggested that thrombocytopenia was likely due to an autoantibody directed against the platelets.

Pathophysiology

The exact pathogenesis of Evans syndrome is not fully understood. It is thought that Evans syndrome is an autoimmune disorder in which autoantibodies are produced against red blood cells and platelets mainly, but also antibodies can be found against neutrophils and lymphocytes.It is also called "immune pancytopenia".[1] On gross pathology, circumscribed mass with microscopic infiltration is a characteristic finding of Evans syndrome. On microscopic histopathological analysis, alternating fibrous and myxoid stroma of low-grade/low malignant potential, and small tumor cells with scanty eosinophilic cytoplasm with a round to oval nuclei and no nucleoli are characteristic findings of Evans syndrome.

Causes

The cause of Evans syndrome has not been identified. It is assumed that excess immune dysregulation is the probable cause of Evans Syndrome.[2]

Differential Evans Syndrome from Other Diseases

Evans syndrome must be differentiated from acquired thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, Kasabach-Merritt syndrome, fibromatosis, fibrosarcoma, myxofibrosarcoma, nodular fasciitis and myxoid neurofibroma. Other differential diagnosis includes: Vitamin defficiencies, Paroxysmal nocturnal hemoglobinuria (PNH) or HELLP (hemolysis-elevated liver enzymes - low platelets) seen in pregnancy.[3]

Epidemiology and Demographics

The incidence of Evan’s Syndrome is not precisely known. Evan’s Syndrome affects male and female equally. Evan’s Syndrome is a rare disease that tends to affect children.

Risk Factors

Natural history, Complications and Prognosis

If left untreated, patients with Evans syndrome have periods of exacerbation. Common complications of Evans syndrome include thrombocytopenia and autoimmune hemolytic anemia. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good.

Diagnosis

History and Symptoms

Symptoms of Evans syndrome include breathlessness, fatigue, jaundice, and dark urine.

Physical Examination

Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Evans syndrome include anemia, direct coombs test positive, and antineutrophil antibody positive.

Following tests are indicated for diagnosis of Evans's syndrome:

Complete blood count, Reticulocyte count, Haptoglobin, LDH, indirect bilirubin, Direct Antiglobulin Test, Monoclonal Antibody Immobilization Platelet Assay (MAIPA), Anti-neutrophil antibodies against CD16/FcγRIII, CD11b, CD35/CR1, CD32/FcγRII[3]

Treatment

Medical Therapy

Pharmacologic medical therapies for Evans syndrome include corticosteroids (prednisone), intravenous immunoglobulin (IVIG), rituximab, anabolic steroids, vincristine, alkylating agents, or cyclosporine.Plasma exchange therapies have also been implicated in its treatment. Refractory disease can be treated by splenectomy and allogeneic hematopoietic stem cell transplant (HSCT).[4][3]

Surgery

Surgery is not the first­line treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment.

References

  1. Pui CH, Wilimas J, Wang W (1980). "Evans syndrome in childhood". J Pediatr. 97 (5): 754–8. doi:10.1016/s0022-3476(80)80258-7. PMID 7191890.
  2. "StatPearls". 2021. PMID 30085557.
  3. 3.0 3.1 3.2 Audia S, Grienay N, Mounier M, Michel M, Bonnotte B (2020). "Evans' Syndrome: From Diagnosis to Treatment". J Clin Med. 9 (12). doi:10.3390/jcm9123851. PMC 7759819 Check |pmc= value (help). PMID 33260979 Check |pmid= value (help).
  4. Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK (2001). "Allogeneic stem cell transplantation for Evans syndrome". Bone Marrow Transplant. 28 (9): 903–5. doi:10.1038/sj.bmt.1703237. PMID 11781654.